<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336840">
  <stage>Registered</stage>
  <submitdate>19/04/2011</submitdate>
  <approvaldate>27/04/2011</approvaldate>
  <actrnumber>ACTRN12611000424909</actrnumber>
  <trial_identification>
    <studytitle>Randomized controlled trial of a new light weight battery operated calf compression device (Venowave) for prevention of venous thrombosis.</studytitle>
    <scientifictitle>Open label randomized controlled trial of a new calf compression device (venowave) versus no Venowave device on background of standard care for prevention of venous thromboembolism in patients undergoing neurosurgery.</scientifictitle>
    <utrn>U1111-1120-8551</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>venous thrombosis prevention in neurosurgery</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Bilateral calf compression devices (Venowave) will be applied within 4 hours of surgery completion and will be continued for up to 24 hours per day (maximum tolerated) for study duration (7 days +/- 2 days). All patients will receive standard care consisting of early mobilization, graduated compression stockings and anticoagulant drugs as determined by their primary doctor.</interventions>
    <comparator>Standard care will consist of early mobilization, bilateral knee length graduated compression stockings (TEDS) and anticoagulant drugs as determined by the primary doctor.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite of asymptomatic deep vein thrombosis (screening venogram or ultrasound) and objectively confirmed symptomatic deep vein thrombosis or pulmonary embolism.</outcome>
      <timepoint>Day 7 (+/- 2 days) or at discharge if earlier</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Venowave tolerability will be assessed using validated patient questionnaire. I addition patients will be questioned regarding device comfort daily using a standardized data sheet. Any adverse events will be documented. Possible adverse events include pruritis, skin irritation or abrasion.</outcome>
      <timepoint>Day 7 (+/- 2 days) or at discharge if earlier</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients undergoing spinal surgery, brain surgery, and patients with intracranial or subdural bleeding with paralysis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>leg ulceration, symptomatic peripheral neuropathy, symptomatic peripheral arterial disease, allergy to contrast medium, renal failure (GFR of less than 50mL/min)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Eligible, consenting patients will be randomized using computer generated randomization sequence concealed in sequentially numbered, opaque sealed envelopes</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>3/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Hamilton Health Sciences</primarysponsorname>
    <primarysponsoraddress>237 Barton Street East
Hamilton ON L8L 2X2</primarysponsoraddress>
    <primarysponsorcountry>Canada</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Golden Horseshoe Network (Government of Ontario)</fundingname>
      <fundingaddress>McMaster University
1200 Main Street West
Michael G. DeGroote Centre for Learning &amp; Discovery,
Room 5105
Hamilton, Ontario
L8N 3Z5</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor John Eikelboom</sponsorname>
      <sponsoraddress>237 Barton Street East
Hamilton ON L8L 2X2</sponsoraddress>
      <sponsorcountry>Canada</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Magdalena Teague</othercollaboratorname>
      <othercollaboratoraddress>237 Barton Street East
Hamilton ON L8L 2X2</othercollaboratoraddress>
      <othercollaboratorcountry>Canada</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of the study is to establish if addition of Venowave devices to standard care in neurosurgical inpatients reduces the risk of venous thrombosis. We also aim to establish if the device is safe and well tolerated by patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hamilton Health Sciences/McMaster Research Ethics Board</ethicname>
      <ethicaddress>Health Science Centre, Room 1B7
McMaster University
1280 Main Street West
Hamilton, Ontario, Canada L8S 4K1</ethicaddress>
      <ethicapprovaldate>17/03/2009</ethicapprovaldate>
      <hrec>1/08/0576</hrec>
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Magdalena Teague</name>
      <address>Hamilton Health Sciences - General Site
237 Barton Street East
Hamilton ON L8L 2X2</address>
      <phone>Phone: +1 905-527-4322 ext 40323</phone>
      <fax />
      <email>mteague@arcbs.redcross.org.au</email>
      <country>Canada</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Magdalena Teague</name>
      <address>Hamilton Health Sciences - General Site
237 Barton Street East
Hamilton ON L8L 2X2</address>
      <phone>Phone: +1 905-527-4322 ext 40323</phone>
      <fax />
      <email>mteague@arcbs.redcross.org.au</email>
      <country>Canada</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>